Head-To-Head Review: Cellect Biotechnology (APOP) and The Competition

Cellect Biotechnology (NASDAQ: APOP) is one of 104 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Cellect Biotechnology to related companies based on the strength of its earnings, dividends, analyst recommendations, valuation, institutional ownership, risk and profitability.

Analyst Ratings

How to Become a New Pot Stock Millionaire

This is a summary of current ratings and target prices for Cellect Biotechnology and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellect Biotechnology 0 0 1 0 3.00
Cellect Biotechnology Competitors 492 1881 3745 115 2.56

Cellect Biotechnology presently has a consensus price target of $14.00, indicating a potential upside of 100.29%. As a group, “Surgical & medical instruments” companies have a potential upside of 10.68%. Given Cellect Biotechnology’s stronger consensus rating and higher probable upside, research analysts plainly believe Cellect Biotechnology is more favorable than its rivals.

Profitability

This table compares Cellect Biotechnology and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellect Biotechnology N/A -153.95% -92.92%
Cellect Biotechnology Competitors -62.26% -47.35% -18.28%

Institutional & Insider Ownership

0.6% of Cellect Biotechnology shares are held by institutional investors. Comparatively, 47.1% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cellect Biotechnology and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cellect Biotechnology N/A -$8.14 million -4.79
Cellect Biotechnology Competitors $1.54 billion $111.80 million -143.19

Cellect Biotechnology’s rivals have higher revenue and earnings than Cellect Biotechnology. Cellect Biotechnology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Cellect Biotechnology has a beta of 4.59, suggesting that its stock price is 359% more volatile than the S&P 500. Comparatively, Cellect Biotechnology’s rivals have a beta of 0.80, suggesting that their average stock price is 20% less volatile than the S&P 500.

Summary

Cellect Biotechnology rivals beat Cellect Biotechnology on 7 of the 13 factors compared.

Cellect Biotechnology Company Profile

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company was founded in 2011 and is headquartered in Kfar Saba, Israel.

Receive News & Ratings for Cellect Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellect Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply